Photo of Marc M. Loriaux, M.D., Ph.D.

Marc M. Loriaux M.D., Ph.D.

Marc Loriaux, M.D., Ph.D. joined the Department of Pathology and Medicine in July, 2003 after completing a fellowship in hematopathology at OHSU. He will help to staff the diagnostic hematopathology service and continue his research in Dr. Brian Druker’s laboratory studying tyrosine kinases as possible therapeutic targets in the treatment of hematologic malignancies.

Education

  • B.A., University of Colorado, Boulder Colorado 1987
  • Ph.D., Oregon Health & Science University, Portland Oregon 1995
  • M.D., Oregon Health & Science University, Portland Oregon 1997
  • Residency:

    • Anatomic and Clinical Pathology, Oregon Health & Science University, Portland, Oregon, 1997-2001
  • Fellowship:

    • Hematopathology, Oregon Health & Science University, Portland, Oregon, 2001-2003
  • Certifications:

    • Anatomic and Clinical Pathology, American Board of Pathology, 2002

Publications

  • "The square stent-based large vessel occluder" Journal of Vascular and Interventional Radiology  2000
  • "Stent-grafts for de novo TIPS" Journal of Vascular and Interventional Radiology  1999
  • "CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability" Blood January 13 2011
  • "Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma" Oncotarget  2015
  • "Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML" Blood September 27 2012
  • "Polyurethane-coated Dacron-covered stentgrafts for tips" CardioVascular and Interventional Radiology November 1998
  • "The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia" Blood November 15 2005
  • "AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance" Cancer Cell November 6 2009
  • "Engineered leucine zippers show that hemiphosphorylated CREB complexes are transcriptionally active" Proceedings of the National Academy of Sciences of the United States of America October 1 1993
  • "Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate" Leukemia March 1 2003
  • "Modulatory function of CREB·CREMα heterodimers depends upon CREMα phosphorylation" Journal of Biological Chemistry November 18 1994
  • "CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms" Blood June 24 2010
  • "Small intestinal submucosa plug for closure of dilated nephrostomy tracts" CardioVascular and Interventional Radiology June 2010
  • "An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma" Biochemical and Biophysical Research Communications September 28 2012
  • "Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms" American Journal of Clinical Pathology May 2011
  • "Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies" Molecular Cancer Therapeutics June 2011
  • "Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles" Cancer Cell December 6 2007
  • "Survey of activated FLT3 signaling in leukemia" PLoS One  2011
  • "TSLP signaling network revealed by SILAC-based phosphoproteomics." Molecular and Cellular Proteomics June 2012
  • "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML" New England Journal of Medicine  2013
  • "Comparison of methods to identify aberrant expression patterns in individual patients" Genome Medicine November 29 2013
  • "BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein" Blood November 20 2014
  • "A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib" Blood January 14 2010
  • "The selective syk inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemias" Journal of Pharmacology and Experimental Therapeutics February 2013
  • "Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib" Leukemia and Lymphoma November 2004
  • "Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia" Experimental Hematology March 2006
  • "Characterization of murine JAK2V617F-positive myeloproliferative disease" Journal of Cancer Research December 1 2006
  • "Bifurcated drum occluder endograft for treatment of abdominal aortic aneurysm" Journal of Vascular and Interventional Radiology  2001
  • "RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia" Blood February 15 2008
  • "Creation of fibrinogen-enhanced experimental blood clots to evaluate mechanical thrombectomy devices for treatment of acute stroke" Journal of Vascular and Interventional Radiology August 2012

Additional information

Edit profile